Nivolumab and Ibrutinib in Treating Patients With Relapsed or Refractory Central Nervous System Lymphoma

Clinical trial NCT03770416 · COMPLETED

Trial details

NCT number: NCT03770416
Sponsor: M.D. Anderson Cancer Center
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Central Nervous System B-Cell Non-Hodgkin Lymphoma Recurrent Central Nervous System Lymphoma Refractory Central Nervous System Lymphoma

Start date: 2019-02-15
Primary completion: 2025-02-10
Enrollment: 18

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.